Jazz Pharmaceuticals PLC (JAZZ) Position Reduced by Renaissance Group LLC

Renaissance Group LLC reduced its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 3.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 92,314 shares of the specialty pharmaceutical company’s stock after selling 3,418 shares during the period. Renaissance Group LLC’s holdings in Jazz Pharmaceuticals PLC were worth $10,065,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in JAZZ. Baird Financial Group Inc. increased its position in Jazz Pharmaceuticals PLC by 6.8% in the fourth quarter. Baird Financial Group Inc. now owns 23,822 shares of the specialty pharmaceutical company’s stock valued at $2,597,000 after buying an additional 1,511 shares during the period. Tredje AP fonden increased its stake in Jazz Pharmaceuticals PLC by 55.1% in the fourth quarter. Tredje AP fonden now owns 2,513 shares of the specialty pharmaceutical company’s stock worth $274,000 after buying an additional 893 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Jazz Pharmaceuticals PLC by 0.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 147,511 shares of the specialty pharmaceutical company’s stock worth $16,082,000 after buying an additional 408 shares during the last quarter. Oxford Asset Management increased its stake in Jazz Pharmaceuticals PLC by 5.1% in the fourth quarter. Oxford Asset Management now owns 39,247 shares of the specialty pharmaceutical company’s stock worth $4,279,000 after buying an additional 1,889 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. acquired a new stake in Jazz Pharmaceuticals PLC during the fourth quarter worth about $295,000. 88.56% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded up 0.86% on Monday, reaching $132.05. 472,085 shares of the company’s stock traded hands. Jazz Pharmaceuticals PLC has a 52 week low of $95.80 and a 52 week high of $160.00. The firm’s 50 day moving average is $119.17 and its 200 day moving average is $120.64. The firm has a market capitalization of $7.91 billion, a P/E ratio of 23.09 and a beta of 1.22.

“Jazz Pharmaceuticals PLC (JAZZ) Position Reduced by Renaissance Group LLC” was first posted by sleekmoney and is the sole property of of sleekmoney. If you are accessing this article on another publication, it was copied illegally and reposted in violation of United States & international copyright & trademark laws. The correct version of this article can be read at http://sleekmoney.com/jazz-pharmaceuticals-plc-jazz-position-reduced-by-renaissance-group-llc/1658872.html.

A number of equities research analysts recently issued reports on the stock. Cantor Fitzgerald set a $187.00 price target on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Wednesday, January 18th. Leerink Swann reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, January 18th. Deutsche Bank AG reaffirmed a “buy” rating and set a $148.00 price target on shares of Jazz Pharmaceuticals PLC in a research note on Thursday, January 19th. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $210.00 price target on shares of Jazz Pharmaceuticals PLC in a research note on Thursday, January 19th. Finally, Guggenheim reaffirmed a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals PLC in a research note on Thursday. Four investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Jazz Pharmaceuticals PLC currently has a consensus rating of “Buy” and an average target price of $179.92.

In other Jazz Pharmaceuticals PLC news, Director Patrick G. Enright sold 677 shares of the business’s stock in a transaction that occurred on Friday, December 2nd. The stock was sold at an average price of $101.80, for a total value of $68,918.60. Following the completion of the sale, the director now owns 1,365 shares in the company, valued at $138,957. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, COO Russell J. Cox sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 18th. The shares were sold at an average price of $128.75, for a total value of $515,000.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,277 shares of company stock valued at $650,161. 3.90% of the stock is owned by company insiders.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/jazz-pharmaceuticals-plc-jazz-position-reduced-by-renaissance-group-llc/1658872.html

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *